Triple Antihypertensive Composition for Better Tolerability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing hypertension treatments often result in poor blood pressure control due to poor adherence, complex guidelines, treatment inertia, and limited potency of monotherapy, leading to increased side effects and reduced tolerability.

Innovation Solution

A pharmaceutical composition comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker, administered at doses ranging from 40% to 150% of the lowest hypertension therapeutic dose, to achieve synergistic therapeutic benefits and improve tolerability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If monotherapy at high doses is used to lower blood pressure, then blood pressure control is improved, but side effects increase and tolerability is reduced

Engineering Contradiction:

Improveblood pressure controlVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent divides the blood pressure control task into three separate pharmacological mechanisms (ARB for angiotensin II blockade, diuretic for fluid balance, and CCB for calcium channel blockade), with each component operating at a lower dose (40-80% of LHTD) to reduce individual side effects while achieving synergistic blood pressure reduction through multiple pathways

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent creates a composite pharmaceutical formulation combining three different antihypertensive agents (ARB, diuretic, and CCB) in specific dose ratios, where the combined effect exceeds the sum of individual effects, allowing each component to work at sub-therapeutic doses that minimize side effects while maintaining overall efficacy

Inventive Principle:

Principle #40Composite materials

2Reliability

If multiple up-titration steps are recommended in treatment guidelines, then blood pressure control is improved, but treatment complexity increases

Engineering Contradiction:

Improveblood pressure controlVSAvoidtreatment guidelines

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent implements combination therapy at initiation with pre-optimized dose ratios (40-80% of LHTD for each component), eliminating the need for sequential monotherapy up-titration steps and providing immediate multi-mechanism blood pressure control from the first treatment step

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent creates a universal initial treatment formulation that addresses multiple blood pressure elevation mechanisms simultaneously (RAAS system, fluid balance, and vascular smooth muscle calcium channels), making the treatment applicable to a broad range of hypertensive patients without requiring complex individualized titration protocols

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If combination therapy is used to improve blood pressure control, then efficacy is improved, but adherence becomes more difficult

Engineering Contradiction:

Improveblood pressure controlVSAvoidadherence

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent merges three separate antihypertensive agents into a single fixed-dose combination tablet with pre-determined optimal dose ratios, allowing patients to take one pill instead of multiple medications, thereby simplifying the regimen and improving adherence while maintaining synergistic blood pressure control

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS12465599B2Compositions for the treatment of hypertension

Publication Date: 2025.11.11 THE GEORGE INST FOR GLOBAL HEALTH

AI summary

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.